You are here

Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44CA189499-02
Agency Tracking Number: R44CA189499
Amount: $1,997,648.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PA14-071
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-08-04
Award End Date (Contract End Date): 2019-07-31
Small Business Information
Arcadia, CA 91006-1839
United States
DUNS: 078776088
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (347) 750-9133
Business Contact
Phone: (347) 750-9133
Research Institution

DESCRIPTION provided by applicant The main commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene c Myc C Myc is a major human oncogene that is estimated to contribute to at least of all human cancers most of which are aggressive and respond poorly to current therapies Despite more than years of research on c Myc the development of drugs that inhibit c Myc has been unsuccessful because the protein is a transcription factor that lacks pockets for small molecules to bind Therefore developing novel treatments that inhibit c Myc is considered one of the most important goals for advancing cancer therapeutics Recently studies from several laboratories including ours have shown that the small ubiquitin like modifications SUMO are critical for c Myc dependent tumorigenesis Therefore our research has focused on inhibiting c Myc by targeting SUMOylation Our initial studies are focused on colorectal cancers because nearly of these cancers depend on c Myc and new therapies are critically needed for metastatic colorectal cancers to improve patient survival SUMOylation is important for c Myc expression by activating catenin Tcf the key transcription factor for inducing c Myc expression in colorectal cancers We have successfully completed the studies proposed for our Phase I SBIR award and have developed a new series of lead compounds that have improved potency and specificity In Phase II studies we propose to conduct necessary pharmacology formulation development Chemistry Manufacturing and Controls work and IND enabling studies At the completion of these preclinical Phase II studies we anticipate being prepared to file an IND application to support further progress toward clinical trials Ultimately development of effective c Myc inhibiting drug would be paradigm shifting for cancer treatment and fill a major void in the market PUBLIC HEALTH RELEVANCE The overall goal is to produce highly potent and specific SUMO activating enzyme inhibitor to treat c Myc dependent

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government